{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:49Z","timestamp":1787628109934,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009793","name":"Chapman University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are chimeric antigen receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory follicular lymphoma (rrFL) after two or more lines of systemic therapy. In the absence of head-to-head clinical trials, this study aimed to compare the efficacy, safety, and cost of axi-cel and tisa-cel in the treatment of rrFL after at least two lines of treatment. Overall response rate (ORR) and safety signals were compared using reporting odds ratios (RORs) with 95% confidence intervals (CIs) at p\u2009&lt;\u20090.05. Progression-free survival (PFS), duration of response (DoR), and overall survival (OS) were compared using the Kaplan?Meier method with a log-rank test. Cost and cost-minimization analyses of drug acquisition, drug administration, serious adverse events (AEs), and relapsed management were calculated. Costs were extracted from the IBM-Micromedex Red Book, Centers for Medicare and Medicaid Services, and existing literature. Statistical analyses were conducted using Microsoft Excel and R version 4.0.5. No statistically significant differences were observed between axi-cel and tisa-cel in terms of ORR, DoR, and OS (p\u2009&gt;\u20090.05). PFS was significantly better with tisa-cel (p\u2009&lt;\u20090.05). Axi-cel was significantly associated with higher incidences of CRS, neurologic events, and grade 3\u20134 AEs than tisa-cel (ROR\u2009&gt;\u20091, p\u2009&lt;\u20090.05). Axi-cel and tisa-cel cost $512,021 and $450,885 per patient, respectively, resulting in savings of US$61,136 with tisa-cel over axi-cel. Tisa-cel appears to have a better safety profile, fewer serious AEs, lower mortality rate, and lower cost than axi-cel.<\/jats:p>","DOI":"10.1007\/s10637-023-01389-w","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T11:02:07Z","timestamp":1691838127000},"page":"710-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-4867","authenticated-orcid":false,"given":"Buthainah","family":"Ghanem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"issue":"3","key":"1389_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3):316\u2013327. https:\/\/doi.org\/10.1002\/ajh.25696","journal-title":"Am J Hematol"},{"key":"1389_CR2","unstructured":"Kaseb H, Ali MA, Koshy NV (2022) Follicular lymphoma. StatPearls. Treasure Island (FL), vol 27. StatPearls Publishing"},{"issue":"3","key":"1389_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"issue":"3","key":"1389_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.13271","volume":"103","author":"R Dada","year":"2019","unstructured":"Dada R (2019) Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol 103(3):152\u2013163. https:\/\/doi.org\/10.1111\/ejh.13271","journal-title":"Eur J Haematol"},{"key":"1389_CR5","unstructured":"National Cancer Institute (NIH). Cancer Stat Facts: NHL \u2014 Follicular Lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html. Accessed December 19 2022"},{"issue":"3","key":"1389_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/hon.2711","volume":"38","author":"J Apostolidis","year":"2020","unstructured":"Apostolidis J, Mokhtar N, Al Omari R, Darweesh M, Al Hashmi H (2020) Follicular lymphoma: update on management and emerging therapies at the dawn of the new decade. Hematol Oncol 38(3):213\u2013222. https:\/\/doi.org\/10.1002\/hon.2711","journal-title":"Hematol Oncol"},{"key":"1389_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early Relapse of Follicular Lymphoma after Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016;34(12):1430] [published correction appears in J Clin Oncol. 2016;34(12):1430]. J Clin Oncol 33:2516\u20132522. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"issue":"1","key":"1389_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.beha.2017.11.003","volume":"31","author":"CY Cheah","year":"2018","unstructured":"Cheah CY, Fowler NH (2018) Novel agents for relapsed and refractory follicular lymphoma. Best Pract Res Clin Haematol 31(1):41\u201348. https:\/\/doi.org\/10.1016\/j.beha.2017.11.003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"1389_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/17474086.2018.1453801","volume":"11","author":"T Erblich","year":"2018","unstructured":"Erblich T, Montoto S (2018) Treating relapsed follicular lymphoma. Expert Rev Hematol 11(5):403\u2013410. https:\/\/doi.org\/10.1080\/17474086.2018.1453801","journal-title":"Expert Rev Hematol"},{"key":"1389_CR10","doi-asserted-by":"publisher","unstructured":"Becnel MR, Nastoupil LJ (2018) Follicular Lymphoma: Past, Present, and Future. Curr Treat Options Oncol. ;19(7):32. Published 2018 May 24. https:\/\/doi.org\/10.1007\/s11864-018-0550-0","DOI":"10.1007\/s11864-018-0550-0"},{"issue":"22","key":"1389_CR11","doi-asserted-by":"publisher","first-page":"01660","DOI":"10.1016\/j.jtct.2022.09.022","volume":"S2666\u20136367","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Ghosh M et al (2022) Assessment of Healthcare Resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with Tisagenlecleucel: results from the ELARA Study [published online ahead of print, 2022 sep 28]. Transpl Cell Ther S2666\u20136367(22):01660\u201301668. https:\/\/doi.org\/10.1016\/j.jtct.2022.09.022","journal-title":"Transpl Cell Ther"},{"key":"1389_CR12","unstructured":"U.S. Food and Drug Administration (FDA) FDA grants accelerated approval of axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. Accessed December 12, (2022) https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma. Accessed December 12, 2022"},{"key":"1389_CR13","unstructured":"U.S. Food and Drug Administration. KYMRIAH (tisagenlecleucel). Accessed December 12, (2022) https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel"},{"issue":"1","key":"1389_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR et al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(1):91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X","journal-title":"Lancet Oncol"},{"issue":"2","key":"1389_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28(2):325\u2013332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","journal-title":"Nat Med"},{"issue":"6","key":"1389_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40259-022-00557-3","volume":"36","author":"B Ghanem","year":"2022","unstructured":"Ghanem B, Shi L (2022) The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma in the US. BioDrugs 36(6):773\u2013780. https:\/\/doi.org\/10.1007\/s40259-022-00557-3","journal-title":"BioDrugs"},{"issue":"1","key":"1389_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/13696998.2021.1901721","volume":"24","author":"R Liu","year":"2021","unstructured":"Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL (2021) Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ 24(1):458\u2013468. https:\/\/doi.org\/10.1080\/13696998.2021.1901721","journal-title":"J Med Econ"},{"issue":"27","key":"1389_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"1389_CR19","unstructured":"IBM Watson, Micromedex IBM (2022) RED BOOK Online. [Database]. http:\/\/www. micro medex solut ions. com. Accessed 16 November 2022"},{"key":"1389_CR20","unstructured":"Centers for Medicare & Medicaid Services (2022) Physician Fee Schedule Final Rule. https:\/\/www.cms.gov\/Medicare\/ Medic are- Fee- for-Servi ce- Payme nt\/ Physi cianF eeSch ed. Published Accessed Novermver 16 2022"},{"issue":"1","key":"1389_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13696998.2021.1894158","volume":"24","author":"CL Simons","year":"2021","unstructured":"Simons CL, Malone D, Wang M et al (2021) Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States. J Med Econ 24(1):421\u2013431. https:\/\/doi.org\/10.1080\/13696998.2021.1894158","journal-title":"J Med Econ"},{"key":"1389_CR22","unstructured":"Centers for Medicare and Medicaid Services (2022) ASP Drug Pricing Files. 2022. https:\/\/www.cms.gov\/medicare\/ medic arepart-b- drug- avera ge- sales- price\/ 2022- asp- drug- prici ng- files. Accessed November 16 2022. (HCPCS J9185)"},{"key":"1389_CR23","doi-asserted-by":"publisher","unstructured":"Potnis KC, Di M, Isufi I et al (2022) Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma [published online ahead of print, 2022 Nov 7]. Blood Adv. ;bloodadvances.2022008097. https:\/\/doi.org\/10.1182\/bloodadvances.2022008097","DOI":"10.1182\/bloodadvances.2022008097"},{"issue":"10","key":"1389_CR24","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1080\/13696998.2018.1489254","volume":"21","author":"GF Guzauskas","year":"2018","unstructured":"Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL (2018) Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. J Med Econ 21(10):960\u2013967. https:\/\/doi.org\/10.1080\/13696998.2018.1489254","journal-title":"J Med Econ"},{"issue":"10","key":"1389_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40273-021-01052-3","volume":"39","author":"C Eichten","year":"2021","unstructured":"Eichten C, Ma Q, Delea TE et al (2021) Lifetime costs for treated follicular lymphoma patients in the US. PharmacoEconomics 39(10):1163\u20131183. https:\/\/doi.org\/10.1007\/s40273-021-01052-3","journal-title":"PharmacoEconomics"},{"issue":"22","key":"1389_CR26","doi-asserted-by":"publisher","first-page":"01704","DOI":"10.1016\/j.jtct.2022.10.009","volume":"S2666\u20136367","author":"J Badaracco","year":"2022","unstructured":"Badaracco J, Gitlin M, Keating SJ (2022) A model to Estimate Cytokine Release Syndrome and neurological event management costs Associated with CAR T-Cell therapy [published online ahead of print, 2022 Oct 19]. Transpl Cell Ther S2666\u20136367(22):01704\u201301703. https:\/\/doi.org\/10.1016\/j.jtct.2022.10.009","journal-title":"Transpl Cell Ther"},{"key":"1389_CR27","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index. Accessed November 16 (2022) https:\/\/www.bls.gov\/cpi"},{"issue":"7","key":"1389_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10(7):74 Published 2020 Jul 17. https:\/\/doi.org\/10.1038\/s41408-020-00340-z","journal-title":"Blood Cancer J"},{"issue":"1","key":"1389_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3960\/jslrt.54.31","volume":"54","author":"K Izutsu","year":"2014","unstructured":"Izutsu K (2014) Treatment of follicular lymphoma. J Clin Exp Hematop 54(1):31\u201337. https:\/\/doi.org\/10.3960\/jslrt.54.31","journal-title":"J Clin Exp Hematop"},{"issue":"3","key":"1389_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/PPO.0000000000000444","volume":"26","author":"S Luminari","year":"2020","unstructured":"Luminari S, Trotman J, Federico M (2020) Advances in treatment of follicular lymphoma. Cancer J 26(3):231\u2013240. https:\/\/doi.org\/10.1097\/PPO.0000000000000444","journal-title":"Cancer J"},{"issue":"11","key":"1389_CR31","doi-asserted-by":"publisher","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","volume":"24","author":"MJ Matasar","year":"2019","unstructured":"Matasar MJ, Luminari S, Barr PM et al (2019) Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist 24(11):e1236\u2013e1250. https:\/\/doi.org\/10.1634\/theoncologist.2019-0138","journal-title":"Oncologist"},{"key":"1389_CR32","doi-asserted-by":"publisher","first-page":"w14635","DOI":"10.4414\/smw.2018.14635","volume":"148","author":"M Bargetzi","year":"2018","unstructured":"Bargetzi M, Baumann R, Cogliatti S et al (2018) Diagnosis and treatment of follicular lymphoma: an update. Swiss Med Wkly 148:w14635. https:\/\/doi.org\/10.4414\/smw.2018.14635. Published 2018 Jul 24","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"1389_CR33","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","volume":"9","author":"C Casulo","year":"2022","unstructured":"Casulo C, Larson MC, Lunde JJ et al (2022) Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol 9(4):e289\u2013e300. https:\/\/doi.org\/10.1016\/S2352-3026(22)00033-3","journal-title":"Lancet Haematol"},{"issue":"10","key":"1389_CR34","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R et al (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28(10):2145\u20132154. https:\/\/doi.org\/10.1038\/s41591-022-01969-y","journal-title":"Nat Med"},{"issue":"3","key":"1389_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11899-015-0267-0","volume":"10","author":"JL Koff","year":"2015","unstructured":"Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR (2015) To each its own: linking the Biology and Epidemiology of NHL subtypes. Curr Hematol Malig Rep 10(3):244\u2013255. https:\/\/doi.org\/10.1007\/s11899-015-0267-0","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"1389_CR36","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835\u20133849. https:\/\/doi.org\/10.1200\/JCO.1999.17.12.3835","journal-title":"J Clin Oncol"},{"key":"1389_CR37","doi-asserted-by":"publisher","unstructured":"Ghielmini M, Vitolo U, Kimby E et al (2013) ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. ;24(3):561\u2013576. https:\/\/doi.org\/10.1093\/annonc\/mds517","DOI":"10.1093\/annonc\/mds517"},{"issue":"8","key":"1389_CR38","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Isgr\u00f2 V, Cutroneo PM et al (2022) Post-marketing Surveillance of CAR-T-Cell Therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf 45(8):891\u2013908. https:\/\/doi.org\/10.1007\/s40264-022-01194-z","journal-title":"Drug Saf"},{"issue":"8","key":"1389_CR39","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00228-021-03106-z","volume":"77","author":"G Bonaldo","year":"2021","unstructured":"Bonaldo G, Montanaro N, AlbertoVaccheri, Motola D (2021) Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. Eur J Clin Pharmacol 77(8):1225\u20131234. https:\/\/doi.org\/10.1007\/s00228-021-03106-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1389_CR40","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1007\/s12325-022-02188-0","volume":"39","author":"AK Cummings Joyner","year":"2022","unstructured":"Cummings Joyner AK, Snider JT, Wade SW et al (2022) Cost-effectiveness of chimeric Antigen receptor T cell therapy in patients with relapsed or refractory large B cell lymphoma: no impact of site of Care. Adv Ther 39(8):3560\u20133577. https:\/\/doi.org\/10.1007\/s12325-022-02188-0","journal-title":"Adv Ther"},{"issue":"2","key":"1389_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mds429","volume":"24","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Nabhan C, Zhou X et al (2013) Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 24(2):441\u2013448. https:\/\/doi.org\/10.1093\/annonc\/mds429","journal-title":"Ann Oncol"},{"key":"1389_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","volume":"9","author":"G Yang","year":"2019","unstructured":"Yang G, Mills M, Kim Y et al (2019) Enhancement of the follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J 9:104. https:\/\/doi.org\/10.1038\/s41408-019-0269-6","journal-title":"Blood Cancer J"},{"issue":"5","key":"1389_CR43","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265. https:\/\/doi.org\/10.1182\/blood-2003-12-4434","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01389-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01389-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01389-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:03:55Z","timestamp":1696676635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01389-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01389-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}